Norstella Launches Real-World Data Agentic Platform and First Agent to Replace Manual Cohort Building

New York – July 28, 2026: Norstella, the leading global provider of pharma intelligence solutions, today announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies.
Norstella Launches Capsul, a Free Daily Intelligence Brief for the Pharma and Biotech Industry

New York – July 28, 2026: Norstella, the leading global provider of pharma intelligence solutions, today announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies.
Norstella Launches Atlas, an Agentic AI Platform Built on Biopharma’s Most Connected Data

New York – July 28, 2026: Norstella, the leading global provider of pharma intelligence solutions, today announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies.
Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development Lifecycle

New York – July 28, 2026: Norstella, the leading global provider of pharma intelligence solutions, today announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies.
Evaluate Recognized for Artificial Intelligence Innovation in 9th Annual AI Breakthrough Awards Program

LONDON, June 25, 2026 – Evaluate, a Norstella company and the leading global provider of market insights for the pharmaceutical industry, today announced that Ask Ella has been named “Enterprise AI Search Solution of the Year” in the 9th annual AI Breakthrough Awards program.
Panalgo Launches IHD Cloud Availability in AWS Marketplace

Boston, MA – May 8, 2025 – Panalgo, a Norstella company dedicated to revolutionizing healthcare data analytics, announced today that Instant Health Data (IHD) Cloud, our real-world evidence platform that is transforming analytics with precision, speed, and efficiency, is now available in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on Amazon Web Services (AWS).
Panalgo and Navidence Partner to Bring Clinical Intelligence to Every Real-World Data Query

Boston, MA – April 29, 2026 – Panalgo, a Norstella company, and Navidence today announced a strategic partnership that embeds Navidence’s validated patient definitions directly into Panalgo’s Instant Health Data (IHD) platform. The collaboration addresses one of the most persistent challenges in real-world data (RWD) analytics, defining diseases and therapies consistently and accurately, by making clinically reviewed phenotype definitions natively available within the analytics workflow.
Recursion Expands Strategic Partnership with Citeline to Advance its AI-Enabled ClinTech Platform

New York and Salt Lake City – Mar. 31, 2026 – Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ: RXRX), a leading tech-bio company decoding biology through advanced data science and automation.
Fred Hassan Appointed Executive Chair of Norstella

New York, New York – Jan. 12, 2026 – Norstella, a leading global provider of pharma intelligence solutions, announced today that healthcare industry leader Fred Hassan has been appointed Executive Chair.
Norstella Appoints Dan Tempesta as Chief Financial Officer

New York, New York – Sept. 9, 2025 – Norstella, a leading global provider of pharma intelligence solutions, has appointed Dan Tempesta as its new Chief Financial Officer. This marks an exciting milestone in Norstella’s journey and underscores the company’s commitment to its next phase of growth.